Meredith M. Regan
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies 82
- Cancer Genomics and Diagnostics 30
- Oncology top 0.2%
- HER2/EGFR in Cancer Research 40
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research 67
- Prostate Cancer Diagnosis and Treatment 43
- Advanced Breast Cancer Therapies 41
- Renal cell carcinoma treatment 31
- Genetics top 0.5%
- Estrogen and related hormone effects 57
- Pathology and Forensic Medicine top 0.5%
- Co-authors
- Richard D. GelberMichael B. AtkinsWilliam OhWanling XieGiuseppe VialeDavid F. McDermottKaren N. PriceAlan S. Coates
- Journals
- New England Journal of Medicine (1 paper)Proceedings of the National Academy of Sciences (1 paper)The Lancet (1 paper)
- Partner nations
- United StatesItalySwitzerland
In The Last Decade
Meredith M. Regan
322 papers receiving 18.0k citations
Hit Papers
Peers
Comparison fields: 5 of 171
- Cancer Research 6.6k
- Oncology 6.7k
- Pulmonary and Respiratory Medicine 7.8k
- Genetics 2.5k
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by Meredith M. Regan
This map shows the geographic impact of Meredith M. Regan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meredith M. Regan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meredith M. Regan more than expected).
Fields of papers citing papers by Meredith M. Regan
This network shows the impact of papers produced by Meredith M. Regan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meredith M. Regan. The network helps show where Meredith M. Regan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Meredith M. Regan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 6 | |
| 7 | 2024 | 6 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 51 | |
| 10 | 2022 | 7 | |
| 11 | 2021 | 21 | |
| 12 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guidelinebreakdown → | 2021 | 592 |
| 13 | 2020 | 21 | |
| 14 | 2020 | 5 | |
| 15 | 2018 | 110 | |
| 16 | 2012 | 102 | |
| 17 | 2011 | 24 | |
| 18 | 2011 | 32 | |
| 19 | 2009 | 164 | |
| 20 | 2008 | 90 |
About Meredith M. Regan
Meredith M. Regan is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 331 papers that have together received 18.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (82 papers), Prostate Cancer Treatment and Research (67 papers), Estrogen and related hormone effects (57 papers), Prostate Cancer Diagnosis and Treatment (43 papers), Advanced Breast Cancer Therapies (41 papers), HER2/EGFR in Cancer Research (40 papers), Renal cell carcinoma treatment (31 papers) and Cancer Genomics and Diagnostics (30 papers). The work is most often cited by research in Cancer Research (6.6k citations), Oncology (6.7k citations) and Pulmonary and Respiratory Medicine (7.8k citations). Meredith M. Regan has collaborated with scholars based in United States, Italy and Switzerland. Frequent co-authors include Richard D. Gelber, Michael B. Atkins, William Oh, Wanling Xie, Giuseppe Viale, David F. McDermott, Karen N. Price, Alan S. Coates, Beat Thürlimann and Aron Goldhirsch. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.